Apexigen Inc. (APGN) Stock
APGN is no longer traded. Apexigen was delisted from the Nasdaq in August 2023.
Prices on this page are historical; the last trade was August 22, 2023 at $0.39.
Apexigen stock price history
APGN final trading statistics
- Final close
- $0.39
- Final trading day
- Aug 22, 2023
- Market cap at delisting
- $9.57M
- Shares outstanding
- 24.86M
- Final 52-week range
- $0.33 – $8.28
- Avg. volume (final 3 mo.)
- 265,447
- All-time high (split-adj.)
- $22.71 · Jul 2022
- All-time low (split-adj.)
- $0.34 · May 2023
- Return since IPO
- -96.4%
- Beta
- 3.62
- Book value / share
- -$0.09
- Price / book
- -4.14
Apexigen annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $0.00 | -$31.5M | -$1.21 |
| FY2021 | $0.00 | -$28.9M | -$0.06 |
| FY2020 | $0.00 | -$23.7M | $0.00 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Apexigen Inc.
Apexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California. As of August 23, 2023, Apexigen, Inc. operates as a subsidiary of Pyxis Oncology, Inc..
Apexigen stock FAQ
What happened to Apexigen stock?
Apexigen stock was delisted from the Nasdaq. Its final close was $0.39 on August 22, 2023.
Is APGN stock still trading?
No. APGN was delisted from the Nasdaq in August 2023 and no longer trades on a U.S. exchange.
What was the last price of APGN stock?
APGN closed at $0.39 on its final trading day, August 22, 2023, for a market value of about $9.57M.
What were Apexigen's revenue and earnings in its last full fiscal year?
Apexigen reported revenue of $0.00 and net income of -$31.5M in fiscal 2022, its last full year as a public company.
When did Apexigen go public?
Apexigen Inc. stock began trading on February 22, 2021.